Abstract
The diabetic foot remains a major cause of morbidity worldwide. Even though considerable progress has been achieved over the past years, there is still an urgent need for improvement. While established therapeutic modalities (revascularization, casting and debridement) remain the mainstay of management, there is, therefore, continuous development of new treatment options. This review provides an outlook of advances in topical treatment, including bioengineered skin substitutes (such as Dermagraft, Apligraf, HYAFF, OASIS and Graftjacket), extracellular matrix proteins (such as Hyalofill and E-matrix), as well as miscellaneous further therapeutic adjuncts. Although promising, new therapies should not, for the time being, constitute the basis of management, since clinical experience has not yet confirmed their effectiveness in hard-to-heal diabetic foot ulcers. Furthermore, their cost-effectiveness merits further investigation. Instead, they should only be considered in combination with established treatments or be attempted when these have not been successful. Moreover, we should not be oblivious to the fact that established and emerging treatments need to be practised in the setting of multidisciplinary foot clinics to reduce the number of amputations.
Keywords: Diabetes mellitus, Diabetic foot, Treatment, Wound healing
Current Diabetes Reviews
Title:Advances in the Topical Treatment of Diabetic Foot Ulcers
Volume: 8 Issue: 3
Author(s): N. Papanas, I. Eleftheriadou, N. Tentolouris and E. Maltezos
Affiliation:
Keywords: Diabetes mellitus, Diabetic foot, Treatment, Wound healing
Abstract: The diabetic foot remains a major cause of morbidity worldwide. Even though considerable progress has been achieved over the past years, there is still an urgent need for improvement. While established therapeutic modalities (revascularization, casting and debridement) remain the mainstay of management, there is, therefore, continuous development of new treatment options. This review provides an outlook of advances in topical treatment, including bioengineered skin substitutes (such as Dermagraft, Apligraf, HYAFF, OASIS and Graftjacket), extracellular matrix proteins (such as Hyalofill and E-matrix), as well as miscellaneous further therapeutic adjuncts. Although promising, new therapies should not, for the time being, constitute the basis of management, since clinical experience has not yet confirmed their effectiveness in hard-to-heal diabetic foot ulcers. Furthermore, their cost-effectiveness merits further investigation. Instead, they should only be considered in combination with established treatments or be attempted when these have not been successful. Moreover, we should not be oblivious to the fact that established and emerging treatments need to be practised in the setting of multidisciplinary foot clinics to reduce the number of amputations.
Export Options
About this article
Cite this article as:
Papanas N., Eleftheriadou I., Tentolouris N. and Maltezos E., Advances in the Topical Treatment of Diabetic Foot Ulcers, Current Diabetes Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339912800563963
DOI https://dx.doi.org/10.2174/157339912800563963 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quality of Life in Individuals with Diabetic Foot Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease
Current Pharmaceutical Design Antineovascular Agents in the Treatment of Eye Diseases
Current Pharmaceutical Design Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress
Current Molecular Pharmacology The Factors Associated with the Length of the Third Stage of Labour: A Descriptive-Analytical Study
Current Women`s Health Reviews Pharmacology of the Human Saphenous Vein
Current Vascular Pharmacology Recent Developments in Antiplatelet Therapy after Percutaneus Coronary Intervention
Cardiovascular & Hematological Disorders-Drug Targets Correlation of Waist to Calf Circumference Ratio and Carotid Intima-Media Thickness in Diabetes Mellitus
Current Diabetes Reviews Hypothalamus-Pituitary-Adrenal (HPA) Axis and Metabolic Abnormalities in First-Episode Psychosis
Current Psychiatry Reviews Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Anti-Diabetic Effects of Isolated Lipids from Natural Sources through Modulation of Angiogenesis
Current Molecular Pharmacology Current Concepts and Controversies in the Use of Antenatal Corticosteroid Therapy for Prevention of Neonatal Morbidities
Current Women`s Health Reviews Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Histamine H3 Receptor Function and Ligands: Recent Developments
Mini-Reviews in Medicinal Chemistry The Role of Melanin to Dissociate Oxygen from Water to Treat Retinopathy of Prematurity
Central Nervous System Agents in Medicinal Chemistry Challenges in Vascular Repair by Endothelial Progenitor Cells in Diabetic Patients
Cardiovascular & Hematological Disorders-Drug Targets “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials